Movers and SHAKERS
Onconova Therapeutics (ONTX)
Looking Forward to Upcoming Clinical Milestones
Onconova Therapeutics Inc is a clinical-stage biopharmaceutical company operating in the US. It focuses on discovering and developing novel small molecule product candidates primarily to treat cancer. The company has created a library of targeted agents designed to work against cellular pathways important to cancer cells. Its product candidates are Single-agent IV rigosertib, Oral rigosertib + azacitidine, IV Briciclib, Recilisib, and ON 123300. The key product candidate Rigosertib is a small molecule which blocks cellular signaling by targeting RAS effector pathways.
Robert LeBoyer, Senior Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Developing drugs to stop the signals that lead to tumor cell growth. Onconova has two drugs in clinical testing, ON 123300 and rigosertib, which target pathways between the cell surface and DNA transcription. These drugs are in clinical trials for both cancers affecting large populations and an orphan tumor. We are maintaining our Outperform rating with a split-adjusted price target of $11 per share.
Clinical trials are progressing. ON 123300 is a multi-kinase inhibitor in development to stop signals in the cell nucleus that lead to cancer cell proliferation. A Phase 1 dose-escalation trial has opened in the US, and a trial in China has dosed its third cohort. Selection of dosing for a Phase 2 clinical trial is expected in 2H21 ...
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.